Supplementary Table S1 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia

Britten K. Gordon; Elizabeth M. Muhowski; Jyotsana Singh; Janani Ravikrishnan; Arnau Peris-Cuesta; Daisy Diaz Rohena; John R. Sanchez; Shanmugapriya Thangavadivel; Samon Benrashid; Alexander He; Alexander R. Marr; Andrew D. Mitchell; Jazmin M. Urrutia; Shrilekha Misra; Tzung-Huei Lai; Lianbo Yu; Brandi R. Walker; Elizabeth Perry; Sachet Ashok Shukla; Nicole Renee Grieselhuber; Kerry A. Rogers; Rosa Lapalombella; James Stewart Blachly; Adam S. Kittai; Seema Ali Bhat; Nitin Jain; William G. Wierda; John C. Byrd; Michael R. Niesman; Kai Zhang; Deepa Sampath; Jennifer Ann Woyach

doi:10.1158/2643-3230.31047012

Supplementary Table S1 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia

2026 Open access

Read full text

Authors: Britten K. Gordon, Elizabeth M. Muhowski, Jyotsana Singh, Janani Ravikrishnan, Arnau Peris-Cuesta, Daisy Diaz Rohena, John R. Sanchez, Shanmugapriya Thangavadivel, Samon Benrashid, Alexander He, Alexander R. Marr, Andrew D. Mitchell

+20 more

Jazmin M. Urrutia, Shrilekha Misra, Tzung-Huei Lai, Lianbo Yu, Brandi R. Walker, Elizabeth Perry, Sachet Ashok Shukla, Nicole Renee Grieselhuber, Kerry A. Rogers, Rosa Lapalombella, James Stewart Blachly, Adam S. Kittai, Seema Ali Bhat, Nitin Jain, William G. Wierda, John C. Byrd, Michael R. Niesman, Kai Zhang, Deepa Sampath, Jennifer Ann Woyach

DOI: 10.1158/2643-3230.31047012

Cited by: 0

Abstract

Characteristics of CLL patients with dual-refractory disease

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Acute Lymphoblastic Leukemia research

Publication details

Publication date: 12 January 2026